In the complexities of the market, finding stocks at lower prices that promise both stability and growth can be daunting....
We are a long way from psychedelic-assisted therapy being taught in American colleges and Universities. However, that doesn’t mean there are no psychedelic...
Cybin moves its lead program forward as it completes enrollment of its Phase 2 study of major depressive disorder. The post Cybin Completes Phase 2 Enrollment...
Cybin Inc. (NYSE American:CYBN) (NEO:CYBN) (“Cybin” or the “Company”), a clinical-stage biopharmaceutical company committed to revolutionizing...
The import to Filament’s Metro Vancouver facility was conducted in collaboration with the Peruvian government and facilitated by Filament Health and...
Seelos Therapeutics has released results from its SLS-002 Phase II study of adults with Major Depressive Disorder at Imminent Risk of Suicide. The post...
–Phase 2 topline efficacy data for CYB003 on track for Q4 2023, followed by U.S. Food and Drug Administration (“FDA”) submission of CYB003 Phase...
Psilo Scientific, a subsidiary of Filament, will use the leaves to research neuropsychiatric applications. The post Filament Brings Coca Leaves to Canada...
This has been a busy quarter for the psychedelic industry, particularly Lucy Scientific Discovery Inc. The company has announced three acquisitions in...
Numinus is ceasing operating activities at Numinus Bioscience and consolidating certain of its clinic operations. The post Numinus Closes Bioscience Lab...
